Gilead Sciences said on April 29 that its experimental anti-viral drug Remdesivir helped improve symptoms in novel coronavirus, or COVID-19, patients who were given the drug early than among those who were treated later.
2/5
Remdesivir is not yet licenced or approved anywhere globally and has not yet been demonstrated to be safe or effective for the treatment of COVID-19.
3/5
Interest in Gilead's drug has been high as there are currently no approved treatments or preventive vaccines for COVID-19, and doctors are desperate for anything that might alter the course of the disease that attacks the lungs and can shut down other organs in extremely severe cases.
4/5
The closely-watched drug has moved markets in the past few weeks. On April 29, broader markets once again rose on the data and Gilead shares also jumped 9 percent.
Gilead said in a statement that it will continue to discuss with regulatory authorities the growing data set regarding Remdesivir as a potential treatment for COVID-19.
